124 related articles for article (PubMed ID: 38159017)
1. [Efficacy and safety of bacterial lysate OM-85 in the treatment of uncomplicated acute respiratory infections: a double-blind, placebo-controlled, multicenter, randomized trial].
Kalyuzhin OV; Gorelov AV; Malyavin AG; Zaytsev AA; Esaulenko EV; Novak KE; Bykov AS
Ter Arkh; 2023 Nov; 95(10):850-858. PubMed ID: 38159017
[TBL] [Abstract][Full Text] [Related]
2. [Ergoferon liquid dosage form--efficacious and safe treatment for childhood acute respiratory infections. Interim outcomes of a multi-center, randomized, double-blind, placebo-controlled clinical trial].
Geppe NA; Kondiurina EG; Galustian AN; Pak TE; Bal'tserovich NB; Zhiglinskaia OV; Kamaev AV; Lazareva SG; Laléko SL; Mel'nikova IM; Perminova OA; Sabitov AU
Antibiot Khimioter; 2014; 59(5-6):6-14. PubMed ID: 25552038
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections.
Esposito S; Bianchini S; Bosis S; Tagliabue C; Coro I; Argentiero A; Principi N
J Transl Med; 2019 Aug; 17(1):284. PubMed ID: 31443716
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR).
Pshenichnaya NY; Bulgakova VA; Lvov NI; Poromov AA; Selkova EP; Grekova AI; Shestakova IV; Maleev VV; Leneva IA
Ter Arkh; 2019 Mar; 91(3):56-63. PubMed ID: 31094461
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Ergoferon in Children from 6 Months to 6 Years Old with Acute Respiratory Viral Infections in Contemporary Outpatient Practice: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial.
Geppe NA; Blokhin BM; Shamsheva OV; Abdrakhmanova ST; Alikhanova KA; Myrzabekova GT
Can Respir J; 2021; 2021():5570178. PubMed ID: 34820034
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
7. [Clinical efficacy of arbidol (umifenovir) in the therapy of influenza in adults: preliminary results of the multicenter double-blind randomized placebo-controlled study ARBITR].
Kiselev OI; Maleev VV; Deeva EG; Leneva IA; Selkova EP; Osipova EA; Obukhov AA; Nadorov SA; Kulikova EV
Ter Arkh; 2015; 87(1):88-96. PubMed ID: 25823275
[TBL] [Abstract][Full Text] [Related]
8. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
10. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
11. Reporting effectiveness of an extract of three traditional Cretan herbs on upper respiratory tract infection: results from a double-blind randomized controlled trial.
Duijker G; Bertsias A; Symvoulakis EK; Moschandreas J; Malliaraki N; Derdas SP; Tsikalas GK; Katerinopoulos HE; Pirintsos SA; Sourvinos G; Castanas E; Lionis C
J Ethnopharmacol; 2015 Apr; 163():157-66. PubMed ID: 25645191
[TBL] [Abstract][Full Text] [Related]
12. [Application of HS221GI in treatment of influenza and ARVI in adults: a new approach - managing virus-induced inflammation. Results of a double-blind, randomized, placebo-controlled, multicenter clinical trial].
Malyavin AG; Bagaeva MI; Kalyuzhin OV
Ter Arkh; 2023 Dec; 95(12):1165-1171. PubMed ID: 38785056
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. A standardized polyphenol mixture extracted from poplar-type propolis for remission of symptoms of uncomplicated upper respiratory tract infection (URTI): A monocentric, randomized, double-blind, placebo-controlled clinical trial.
Esposito C; Garzarella EU; Bocchino B; D'Avino M; Caruso G; Buonomo AR; Sacchi R; Galeotti F; Tenore GC; Zaccaria V; Daglia M
Phytomedicine; 2021 Jan; 80():153368. PubMed ID: 33091857
[TBL] [Abstract][Full Text] [Related]
15. Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a double-blind, placebo-controlled multicenter study.
Schaad UB; Mütterlein R; Goffin H;
Chest; 2002 Dec; 122(6):2042-9. PubMed ID: 12475845
[TBL] [Abstract][Full Text] [Related]
16. Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging study.
Bachert C; Chuchalin AG; Eisebitt R; Netayzhenko VZ; Voelker M
Clin Ther; 2005 Jul; 27(7):993-1003. PubMed ID: 16154478
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, double-blind, parallel group, randomized placebo-controlled trial.
Raj JP; Maurya MR; Nair N; Marfatia H; Hadaye R; Gogtay NJ
Complement Ther Med; 2023 May; 73():102934. PubMed ID: 36842634
[TBL] [Abstract][Full Text] [Related]
18. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the efficacy and safety of a complex antiviral drug based on antibodies in the treatment of adult patients with acute respiratory viral infection].
Khamitov RF; Nikiforov VV; Zaytsev AA; Tragira IN
Ter Arkh; 2022 Jan; 94(1):83-93. PubMed ID: 36286922
[TBL] [Abstract][Full Text] [Related]
20. Primary prevention of acute respiratory tract infections in children using a bacterial immunostimulant: a double-masked, placebo-controlled clinical trial.
Jara-Pérez JV; Berber A
Clin Ther; 2000 Jun; 22(6):748-59. PubMed ID: 10929921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
